RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes which are responsible for diseases. Currently, the awareness about RNAi is increasing extensively due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development.

Market leaders operating in the market have undertaken various organic growth strategies in the RNAi therapeutics market. The RNAi therapeutics market majorly consists of the players such Alnylam Pharmaceuticals, Inc., Sanofi, Olix Pharmaceuticals, Inc., Glaxosmithkline Plc., Benitec Biopharma, Arbutus Biopharma Corporation, Silence Therapeutics, Rexahn Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc, and Quark amongst others. Several organic approaches, such as product launches, and expansion/relocation in the RNAi therapeutics market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.

Below is the list of the growth strategies done by the players operating in the RNAi therapeutics market:




Alnylam Pharmaceuticals, Inc got FDA approval for its Givlaari, a very first subcutaneously administered RNAi therapy for the treatment of acute hepatic porphyria (AHP).


Benitec Biopharma completed phase 2 clinical trial of its RNAi therapy candidate BB-401 for the treatment of head and neck squamous cell carcinoma (HNSCC). The study was conducted in Russia and Australia.


OliX Pharmaceuticals, Inc. got clinical trial approval from Medicines and Healthcare products Regulatory Agency (MHRA), UK to conduct phase 1 trial for the drug candidate OLX10010. Olix Pharma is developing this drug for the treatment of hypertrophic scar.


Rexahn Pharmaceuticals, Inc. received New U.S. Patent for Supinoxin which is a small molecule modulator of the β-catenin pathway- a key biological pathway that is activated in tumor cells.